ANDA Pipeline: Drug Commercialization

The Abraxis Pharmaceutical Products division has one of the most active product development programs in the industry. In the first half of 2006, eight approvals have been received from the US FDA. In the past five years, APP had 51 product approvals making it an industry leader.

Seventeen oncology products, 26 critical care products, and 20 anti-infective products are currently in development.